Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 107-96-0 Chemical Structure| 107-96-0

Structure of 3-Mercaptopropionic acid
CAS No.: 107-96-0

Chemical Structure| 107-96-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Chen, Jing ; Ji, Peng ; Gnawali, Giri ; Chang, Mengyang ; Gao, Feng ; Xu, Hang , et al.

Abstract: The current targeting drug delivery mainly relies on cancer cell surface receptors. However, in many cases, binding affinities between protein receptors and homing ligands is relatively low and the expression level between cancer and normal cells is not significant. Distinct from conventional targeting strategies, we have developed a general cancer targeting platform by building artificial receptor on cancer cell surface via a chemical remodeling of cell surface glycans. A new tetrazine (Tz) functionalized chemical receptor has been designed and efficiently installed on cancer cell surface as "overexpressed" biomarker through a metabolic glycan engineering. Different from the reported bioconjugation for drug targeting, the tetrazine labeled cancer cells not only locally activate TCO-caged prodrugs but also release active drugs via the unique bioorthogonal Tz-TCO click-release reaction. The studies have demonstrated that the new drug targeting strategy enables local activation of prodrug, which ultimately leads to effective and safe cancer therapy.

Keywords: Artificial receptor ; Click and release ; Local activation ; Protein degradation

Alternative Products

Product Details of [ 107-96-0 ]

CAS No. :107-96-0
Formula : C3H6O2S
M.W : 106.14
SMILES Code : O=C(O)CCS
MDL No. :MFCD00004897
InChI Key :DKIDEFUBRARXTE-UHFFFAOYSA-N
Pubchem ID :6514

Safety of [ 107-96-0 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H290-H301-H314-H332-H401
Precautionary Statements:P234-P261-P264-P270-P271-P273-P280-P301+P310+P330-P301+P330+P331-P303+P361+P353-P304+P340+P310-P305+P351+P338+P310-P363-P390-P405-P406-P501
Class:8(6.1)
UN#:2922
Packing Group:

Computational Chemistry of [ 107-96-0 ] Show Less

Physicochemical Properties

Num. heavy atoms 6
Num. arom. heavy atoms 0
Fraction Csp3 0.67
Num. rotatable bonds 2
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 26.24
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

76.1 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.82
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.43
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.39
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.03
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.13
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.36

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.64
Solubility 24.5 mg/ml ; 0.231 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.6
Solubility 2.69 mg/ml ; 0.0254 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.1
Solubility 83.3 mg/ml ; 0.785 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.64 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.28

Application In Synthesis of [ 107-96-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 107-96-0 ]

[ 107-96-0 ] Synthesis Path-Downstream   1~11

  • 1
  • [ 625-51-4 ]
  • [ 107-96-0 ]
  • [ 52574-08-0 ]
YieldReaction ConditionsOperation in experiment
With trifluoroacetic acid; 3-((acetamidomethyl)sulphanyl)propanoic acid (Acm) (IV.2) 3-mercaptopropanoic acid (1.64 ml; 19 mmol) is dissolved into trifluoroacetic acid (30 ml). <strong>[625-51-4]N-(hydroxymethyl)acetamide</strong> (1.6 g; 19 mmol) is next added. After stirring for 30 minutes at room temperature, TFA is evaporated off to obtain IV.2: HPLC tR 7.1 min. (linear gradient, 5-65% B, 20 min); 1H NMR (300 MHz, CDCl3, 298 K) delta 12.4 (s, COOH, 1H); 7.74 (d, NH, J=5.8 Hz, 1H); 4.34 (d, SCH2NH, J=6 Hz, 2H); 2.81 (t, CH2SCH2NH, J=6.4 Hz, 2H); 2.67 (t, CH2COOH, J=6.4 Hz, 2H); 2.1 (s, NHCOCH3, 3H); 13C NMR (300 MHz, CDCl3, 298 K) 177.45 (CO); 174.63 (CO); 41.60 (CH2); 34.37 (CH2); 25.67 (CH2); 21.46 (CH3).
  • 2
  • [ 67-56-1 ]
  • [ 107-96-0 ]
  • [ 15441-06-2 ]
  • 3
  • [ 555-60-2 ]
  • [ 107-96-0 ]
  • 3-{2-[(3-Chloro-phenyl)-hydrazono]-2-cyano-acetimidoylsulfanyl}-propionic acid [ No CAS ]
  • 4
  • [ 17696-69-4 ]
  • [ 107-96-0 ]
  • 7,12-bis<1-<(2-carboxyethyl)thio>ethyl>-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoic acid [ No CAS ]
  • 5
  • [ 60940-34-3 ]
  • [ 107-96-0 ]
  • S-(2-phenylcarbamoyl-phenylselenyl)-3-mercaptopropionic acid [ No CAS ]
YieldReaction ConditionsOperation in experiment
EXAMPLE 4 S-(2-phenylcarbamoyl-phenylselenyl)-3-mercaptopropionic acid Prepared similar to example 1 from 5 g (18,2 mmol) of 2-phenyl-1,2-benzisoselenazole-3(2H)-one and 2 g (18,9 mmol) of 3-mercaptopropionic acid. Yield: 5,85 g (85% of the theory), m.p. 203-204 C.
  • 6
  • [ 38222-83-2 ]
  • [ 77758-76-0 ]
  • [ 107-96-0 ]
  • 3-pentafluoroethylthiopropionic acid [ No CAS ]
YieldReaction ConditionsOperation in experiment
In dichloromethane; REFERENCE EXAMPLE 4 2.0 ml of methylene chloride, 0.05 ml (0.58 mmol) of 3-mercaptopropionic acid and 120 mg (0.59 mmol) of <strong>[38222-83-2]2,6-di-tert-butyl-4-methylpyridine</strong> were charged in a flask, and 261 mg (0.55 mmol) of pentafluoroethylphenyliodonium trifluoromethanesulfonate was added thereto in small portions while stirring at room temperature, followed by stirring the mixture at room temperature for 20 minutes. The resulting white precipitate was filtered, subjected to column chromatography of a small amount of silica gel and, after eluding iodobenzene with hexane, the desired product was eluted with diethyl ether. Diethyl ether was distilled off from the elude to obtain 3-pentafluoroethylthiopropionic acid as a colorless liquid. A sample of the product was purified by gas chromatography. Yield, 83percent. 19 F-NMR (CCl3 F internal standard in CDCl3): -84.00 ppm (t, JCF3,CF2 =3.5 Hz, CF3, 3F), -92.82 ppm (q, JCF3,CF2 =3.5 Hz, CF2, 2F) 1 H-NMR (in CDCl3): 2.79 ppm (t, J=7.0 Hz, CH2 SC2 F5, 2H), 3.15 ppm (t, J=7.0 Hz, --CH2 CO--, 2H), 10.6 ppm (br.s, CO2 H, 1H). IR (neat): 3050 (broad absorption), 2670, 2480, 1720, 1430, 1330, 1215, 1100, 970, 920, 810, 750, 650, 625, 585, 555 cm-1. MS: 224 (M+), 179, 105, 87, 69, 63, 59, 45. Elementary Analysis: Found: C, 26.83; H, 2.31percent. Calc'd: C, 26.79; H, 2.25percent.
  • 7
  • [ 2645-22-9 ]
  • [ 107-96-0 ]
  • [ 192331-71-8 ]
  • 8
  • [ 391-12-8 ]
  • [ 95-51-2 ]
  • [ 107-96-0 ]
  • [ 1373763-20-2 ]
YieldReaction ConditionsOperation in experiment
92% With 1-methylimidazolium tetrafluoroborate; at 140℃; for 0.05h;Microwave irradiation; Ionic liquid; Pyrex glass vial containing an equimolar mixture (5 mmol) of appropriate indole-2,3-dione (1) and substituted aniline (2) and thioacids (3a/b) adsorbed on 1-methylimidazolium tetrafluoroborate ([MIM]+BF4-) (1 gm) was placed in a screw capped Teflon vessel. Microwave was applied for 5 min at 140 °C. After the completion of reaction (TLC analysis), recyclable ionic liquid was separated by filtration after eluting the product with ethanol under reduced pressure and the residue washed with methanol gave a pure product in high yield (Table 1). All synthesized compounds were characterized by spectral analysis and data summarized in Table 4.
  • 9
  • [ 64987-85-5 ]
  • [ 107-96-0 ]
  • MPr-SMCC [ No CAS ]
YieldReaction ConditionsOperation in experiment
95% With N-ethyl-N,N-diisopropylamine; The drug-linker SMCC-MDC was prepared in the following reactions: (1) 3-mercaptopropanoic acid (MPr) was reacted with N-succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC) in the presence of N,N-diisopropylethylamine (DIEA), giving the MPr-SMCC at a yield of over 95percent;
95% With N-ethyl-N,N-diisopropylamine; The drug-linker SMCC-MDC was prepared in the following reactions: (1) 3-mercaptopropanoic acid (MPr) was reacted with N-succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC) in the presence of N,N-diisopropylethylamine (DIEA), giving the MPr-SMCC at a yield of over 95percent;
95% With N-ethyl-N,N-diisopropylamine; The drug-linker SMCC-MDC was prepared in the following reactions: (1) 3-mercaptopropanoic acid (MPr) was reacted with N-succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC) in the presence of N,N-diisopropylethylamine (DIEA), giving the MPr-SMCC at a yield of over 95percent;
> 95% With N-ethyl-N,N-diisopropylamine; The drug-linker SMCC-MDC was prepared in the following reactions: (1) 3-mercaptopropanoic acid (MPr) was reacted with N-succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC) in the presence of DIEA, giving the MPr-SMCC at a yield of over 95percent; Secondly, condensation of N-Me-L-Ala-MDC, which was prepared by deprotection of Fmoc-N-Me-Ala-MDC under a base piperidine in CH3CN, with MPr-SMCC under a coupling reagent EDC, giving the desired coupled product SMCC-MDC in 60-70percent yield over two steps. Antibody Bat0206 (Abu) was diluted to 2.5 mg/mL in solution A (50 mM potassium phosphate, 50 mM NaCl, and 2 mM EDTA, pH 6.5). SMCC-MDC was added to give a ratio of SMCC-MDC to antibody of 7:1 mole equivalent. Then DMA was added to 15percent (v/v) to the reaction and reaction was mixed by stirring for 4 h at ambient temperature. D-Lmcc-Bat0206 conjugate was purified from excess unreacted or hydrolyzed reagent and excess SMCC-MDC using a G25 gel filtration column equilibrated in pH 7.4 phosphate buffer (aqueous). The conjugate was then dialyzed overnight into pH 7.4 phosphate buffer (aqueous) and then filtered through a 0.22 mum filter for final storage. The number of SMCC-MDC molecule per Abu molecule in the final conjugate was measured by determining absorbance of the conjugate at 252 and 280 nm and using known extinction coefficients for SMCC-MDC and antibody at these two wavelengths. A ratio of maytansinoid compound to antibody of 3.5:1.0 was normally obtained.
95% With triethylamine; In dichloromethane; at 20℃; for 2h; In the solution of SMCC (3 g) in anhydrous CH2Cl2 (80 ml), mercaptoacetic acid (0.937 ml) and triethylamine (1.428 ml) wereadded. The mixture was stirred for 2 h at room temperature. After evaporation of the solvent under vacuum, the solid was purified by column chromatography (CH2Cl2:Methanol = 20:1) to yield compound 2(3.76 g, 95percent). The structure was identified by ESI-QTOF-MS, 1H and 13C NMR. (M + H)+ = 441.1591; (M + Na)+ = 463.1132. 1H NMR(400 MHz, DMSO-d6): delta 12.33 (s, 1H), 4.02 (1H,dd, J = 8.9, 3.8 Hz), 3.25(d,2H, J = 7.0 Hz), 3.22?3.13 (m, 1H), 2.94 (dd,1H,J = 13.5, 6.7 Hz),2.86 (dd,1H,J = 13.7, 6.7 Hz), 2.8 (s,3H), 2.69 (t,1H,J = 12.0 Hz), 2.62?2.44 (m, 4H), 2.00 (d,2H,J = 11.1 Hz), 1.69 (d,3H,J = 13.3 Hz), 1.48?1.27 (m, 2H), 1.05 (dd,2H,J = 23.6, 11.0 Hz). 13C NMR (100 MHz,DMSO-d6): delta 177.0, 175.3, 172.8, 170.8, 170.2, 43.7, 35.6, 34.9, 34.0, 28.5,27.8, 26.8, 25.4.

  • 10
  • [ 141403-49-8 ]
  • [ 107-96-0 ]
  • C17H25NO4S [ No CAS ]
YieldReaction ConditionsOperation in experiment
With sodium hydroxide; In N,N-dimethyl-formamide; at 50℃; for 5.0h; To the solution of compound 13a (0.5g, 1.23mmol) in DMF, 3- mercaptopropanoic acid, 9 (0.157g, 1.48mmol) was added. To this mixture, IN NaOH (2 mL) was added and reaction was allowed to stir at 50 C for 5 h. The crude product 14a was obtained by evaporating the solvent and was used for the next step without any further purification. LCMS m/z calculated for 14a: C17H25NO4S [M+Na]+: 362.15, found 362.17. LCMS m/z calculated for 14b: C19H26N2O4S [M-H+] : 378.20, found 377.14.
  • 11
  • [ 207399-07-3 ]
  • [ 107-96-0 ]
  • C39H49N2O2S(1+)*I(1-) [ No CAS ]
YieldReaction ConditionsOperation in experiment
In dimethyl sulfoxide; at 45℃; for 4h;Inert atmosphere; Add 0.4mmol compound 3 to a 50mL reaction flask, add 10mL dimethylsulfoxide (DMSO) and stir to dissolve, then add 0.8mmol mercaptopropionic acid, heat to 45, dissolve, and react for 4h under argon protection; After the reaction, 0.12 mmol each of Compound 2, NHS and DCC was added to the mixed solution, and the reaction was stirred at 45 C. for 4 hours, and the reaction was completed. The reaction solution was poured into 50 mL of methyl tert-butyl ether, a green solid was precipitated, and the upper solid was collected by filtering with filter paper. 200-300 mesh silica gel column chromatography for separation and purification. The eluent is a mixture of dichloromethane and methanol with a volume ratio of 25:1 to obtain 11.5 mg of green metallic crystals as near-infrared fluorescent probes
 

Historical Records